LONDON, April 29—Two U.S.-based healthcare public relations firms—Chamberlain Communications in New York and Spectrum Science in Washington, D.C.—have joined GlobalHealthPR, a network of independent healthcare PR consultants that will unite seven firms on three continents with 180 professionals and $28 million in revenues.
“GlobalHealthPR is unique” says Liz Shanahan, founder and chair of GlobalHealthPR, and managing director of her own consultancy, Santé Communications, based in London. “Each partner is well-established and independently successful, specializing exclusively on health brands and health issues. GlobalHealthPR offers clients the best of all worlds—the ability to deliver global core communications programs, complemented by a genuine ability to implement locally.”
Member companies include Santé Communications, Chamberlain Communications Group, Spectrum Science Public Relations, GroupePR of Paris; FischerAppelt Kommunikation, which is headquartered in Hamburg but operates in four other markets in Germany, PRForce of Brussels and the Netherlands, and Inoue Public Relations of Tokyo.
Together, the firms serve clients including AstraZeneca, Aventis, Biogen, Bristol-Myers Squibb, Eli Lilly, Pfizer, GlaxoSmithKline, Merck, Novartis, Roche, Schering-Plough and 3M.
“The concept is valuable because it offers comprehensive reach globally that is strategically focused for each core market,” according to Beatrice Cookson, global licensing director for Roche. “PR strategy is a key element to communication success and we consider a most crucial element. We need consistent communications, across continents and cultures. I find the promise made on paper by the multinational agencies is rarely fulfilled. A group like this, made up of independently successful companies specific to each culturally unique market offers the client a proven communications group that can maximize impact within the local markets.”
According to Chamberlain Communications president Richard Chamberlain, “GlobalHealthPR is addressing today’s multinational health businesses that expect greater scientific expertise, increased health care marketing savvy, and more efficient global reach than they now enjoy from conglomerates.”